Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy with 111-In-Pentetreotide
Abstract
Somatostatin (SST) is a peptide hormone implicated in the growth and progression of cancers and SSTR2 is the predominant receptor subtype expressed in breast cancer. We hope to study the feasibility and efficacy of radiolabelled somatostatin analogs in breast cancer. To this end, we have developed an algorithm called AQUA that can assess protein expression on tissue microarrays (TMA) based on molecular co-localization techniques. Our results show that SSTR2 is variably expressed in a large proportion of breast cancers and is predominantly within the membrane compartment of tumors not stroma. Although expression was not significantly correlated with survival on our TMA, it did appear to be overexpressed in malignant breast epithelium compared with benign breast tissue. We will quantitate protein measurement even further with correlations with cultured cell line expression of SSTR2. We have also begun efforts to incorporate our techniques clinically by opening a clinical trial in patients with breast cancer to analyze our methodologies for SSTR2 expression with more traditional methods. Ultimately, our plan is to compare the different measures of SSTR2 expression on predicting response/survival in a clinical trial of radiolabelled SST analogue (111-In-pentetreotide) in patients with metastatic breast cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2005
- Accession Number
- ADA436873
Entities
People
- David L Rimm
- Gina G. Chung
- John Murren
Organizations
- Yale University